Idera Pharmaceuticals, Inc. Announces Formation Of Oncology Clinical Advisory Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 25, 2006--Idera Pharmaceuticals (AMEX: IDP - News) today announced the formation of its Oncology Clinical Advisory Board (OCAB). Idera's OCAB is comprised of an internationally prominent group of physicians and scientists with expertise in all aspects of oncology drug development and clinical practice. The OCAB has been established to advise the company on its Toll-like Receptor (TLR) targeted development programs in oncology, including its lead drug candidate, IMO-2055, which is currently in clinical evaluation for renal cell carcinoma and non-small cell lung cancer.

Back to news